ResMed's AirSense 11 platform and myAir app enhance patient engagement and efficiency. Check out why I remain bullish on RMD ...

ResMed (NYSE:RMD) shares fell Wednesday after Wolfe Research downgraded the MedTech, citing risks to the company’s CPAP ...

Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target ...

Apple released watchOS 11 today following months of beta testing. A key new health-related feature included in the software ...

A new survey shows that more than half of people diagnosed with obstructive sleep apnea (OSA) aren’t satisfied with their ...

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.

In a report released today, Michael Matson from Needham maintained a Hold rating on Resmed (RMD – Research Report). The company’s ...

Shares of ResMed Inc. RMD rallied 5.84% to $208.54 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.08% to 5,463.54 and ...

For ResMed, which makes masks and continuous-positive-airway-pressure, or CPAP, machines ... in April that those who take GLP ...

ResMed Inc. ’s RMD growth is backed by its impressive global Mask sales growth. Of late, the company has been experiencing increased Device sales, reflecting the ongoing combined availability of ...